CAJ | 학술논문

目的探讨硼替佐米(BTZ)对人类皮肤T细胞淋巴瘤Hut-78细胞系的细胞毒作用及其与吡柔比星(THP)联合应用的抗肿瘤效果.方法采用MTT法观察BTZ、THP单药及两药联合不同给药顺序对Hut-78细胞增殖的抑制作用,利用中效方程分析两药是否存在协同效应.结果 BTZ、THP单药均能有效抑制Hut-78细胞的生长,且呈时间和剂量依赖性,培养48 h的半数抑制浓度分别为8.53 nmol/L和2515.27 μg/L.两药联合具有显著的抗肿瘤活性,当增殖抑制率＞50%时,THP序贯BTZ呈现拮抗效应,而BTZ与THP同时及BTZ序贯THP均具有协同效应,后者的抗肿瘤作用更为显著.结论 BTZ单药及其与THP联合体外可有效抑制T细胞淋巴瘤细胞增殖.BTZ是一种很有前景的治疗T细胞淋巴瘤的靶向药物,为BTZ与THP联合治疗T细胞淋巴瘤的临床研究提供了实验依据.
목적 탐토붕체좌미(BTZ)대인류피부T세포림파류Hut-78세포계적세포독작용급기여필유비성(THP)연합응용적항종류효과.방법 채용MTT법관찰BTZ、THP단약급량약연합불동급약순서대Hut-78세포증식적억제작용,이용중효방정분석량약시부존재협동효응.결과 BTZ、THP단약균능유효억제Hut-78세포적생장,차정시간화제량의뢰성,배양48 h적반수억제농도분별위8.53 nmol/L화2515.27 μg/L.량약연합구유현저적항종류활성,당증식억제솔＞50%시,THP서관BTZ정현길항효응,이BTZ여THP동시급BTZ서관THP균구유협동효응,후자적항종류작용경위현저.결론 BTZ단약급기여THP연합체외가유효억제T세포림파류세포증식.BTZ시일충흔유전경적치료T세포림파류적파향약물,위BTZ여THP연합치료T세포림파류적림상연구제공료실험의거.
Objective To investigate the cytotoxic effect of bortezomib(BTZ)on human cutaneous T-cell iymphoma Hut-78 cell line and the antitumor activity of BTZ combined with pirarubicin(THP)on tumor cells.Methods The effects of BTZ,THP alone,or BTZ plus THP,on the proliferation of Hut-78 cells were determined by MTr assay.Results BTZ and THP alone effectively induced growth inhibition of Hut-78 cells in a time-and dose-dependent manner,with an 50 % inhibiting concentration of 8.53 nmol/L and 2515.27 μg/L individually after 48 hours of culture.BTZ plus THP had an impressive antitumor efficacy compared with single agent.The combination index analysis showed significant synergistic effects when treated with BTZ followed by THP and concurrent BTZ plus THP,especially for the former.Conclusion BTZ alone or combined with THP significantly inhibited the growth of Hut-78 cells in vitro.Our study demonstrated that BTZ plus THP presents a synergistically antitumor effect on T cell lymphoma cells and may be an optimal regimen in clinical trial of T cell lymphoma.